Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.530NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-20229.7US
B.1.530NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.570NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.570NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAYNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.570NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.570NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-20634.9US
DD.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DD.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
DD.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DD.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAYNUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XAYNUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XAYNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAYNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAYNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XAYNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.75.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DD.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
DD.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.633NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.633NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.75.8NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
BA.2.75.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.75.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.75.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.75.8NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.75.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DD.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CH.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
CH.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.570NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.570NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
CH.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.633NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.633NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.633NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.633NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.633NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-23398.4US
B.1.633NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-17055.8US
BA.1.17.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-713.74US
BA.1.17.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
BA.1.17.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.17.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used